Compare UFPT & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFPT | VCEL |
|---|---|---|
| Founded | 1963 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1993 | 1997 |
| Metric | UFPT | VCEL |
|---|---|---|
| Price | $223.89 | $36.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $289.00 | $60.40 |
| AVG Volume (30 Days) | 130.6K | ★ 611.9K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.11 | ★ 236.54 |
| EPS | ★ 8.61 | 0.25 |
| Revenue | ★ $597,952,000.00 | $258,716,999.00 |
| Revenue This Year | $21.91 | $17.86 |
| Revenue Next Year | $5.39 | $18.55 |
| P/E Ratio | ★ $25.34 | $143.95 |
| Revenue Growth | ★ 29.47 | 14.05 |
| 52 Week Low | $178.26 | $29.24 |
| 52 Week High | $289.57 | $63.00 |
| Indicator | UFPT | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 45.75 |
| Support Level | $213.72 | $34.79 |
| Resistance Level | $222.04 | $37.11 |
| Average True Range (ATR) | 8.27 | 1.40 |
| MACD | -0.25 | -0.33 |
| Stochastic Oscillator | 80.70 | 29.60 |
UFP Technologies Inc is a designer and custom manufacturer of components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics for the medical market. The company manufactures its products by converting raw materials using laminating, molding, radio frequency and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.